|
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Clinical research trials and Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies. Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies  Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
For Condition: Hematologic Malignancies
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center , Chiron Corporation
Synopsis: The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.
Details: Patients with leukemias that have relapsed from previous therapies have a low cure rate. Hence the need to discover new antileukemic agents. Tezacitabine is a nucleoside analogue with equivalent or even superior activity when compared with ara-C in leukemic cell lines. It has shown significant antitumor activity in vitro and in vivo tumor models. Several phase I studies with various dosing schedules have been conducted in solid tumors where the DLT is mainly myelosuppression, usually a favorable feature for development of leukemia. In a phase I study in hematological malignancies, we used Tezacitabine as a bolus infusion daily x 5. The DLT consisted of grade 3 CNS toxicities and mucositis in 3/6 patients. The study is ongoing and we are currently evaluating a dose level of 7.5 mg/m2 as possible MTD. However, in view of the fact that tezacitabine is a cell cycle specific agent with a short terminal plasma half-life of 2 to 6 hours, a continuous infusion dosing schedule may enhance the activity and reduce the incidence of adverse effects of tezacitabine.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 15 Years/
Genders: Both
Protocol Entry Criteria: - Patient with relapsed/refractory acute leukemias (AML, ALL, high-grade myelodysplastic syndromes, CMML in transformation with >/= 10% peripheral blood/bone marrow blasts, CML in blast crisis), or patients with relapsed/refractory CLL and an absolute neutrophil count of >/= 1,000/ml and platelet count of >/= 75,000/ml. - Signed informed consent indicating that patients are aware of the investigational nature of this study, and in keeping with the policies of this hospital. The only acceptable consent form is attached at the end of this protocol. - Age >/= 15 years. - ECOG performance status
Total Enrollment: 30
Location and Contact Information:
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: ID01-168;
Study Start Date: September 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061620
Other Hematologic Malignancies Studies:
1. Stem Cell Transplant for Patients with Hematologic Malignancy Using Family Donors and Conditioning with Campath-1H
2. IUdR/BUdR cell cycle labelling
3. Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
Related Studies:
Other Hematologic Malignancies Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
|
|
|
|
|
|
|
